Initiator Pharma A/S (INIT.ST)
SEK 5.95
(0.0%)
SEK 5.95
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3617.00 DKK | -99.89% |
| 2022 | 3.31 Million DKK | 129.25% |
| 2021 | 1.44 Million DKK | 17.37% |
| 2020 | 1.23 Million DKK | 26.62% |
| 2019 | 973 Thousand DKK | -17.12% |
| 2018 | 1.17 Million DKK | -14.99% |
| 2017 | 1.38 Million DKK | 638.5% |
| 2016 | 187 Thousand DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 676 Thousand DKK | 42496.09% |
| 2024 Q2 | 1.33 Million DKK | 97.34% |
| 2023 Q3 | 687 Thousand DKK | -1.72% |
| 2023 Q4 | 1587.00 DKK | -99.77% |
| 2023 FY | 3617.00 DKK | -99.89% |
| 2023 Q1 | 644 Thousand DKK | -33.47% |
| 2023 Q2 | 699 Thousand DKK | 8.54% |
| 2022 Q4 | 968 Thousand DKK | -16.98% |
| 2022 FY | 3.31 Million DKK | 129.25% |
| 2022 Q3 | 1.16 Million DKK | 72.74% |
| 2022 Q2 | 675 Thousand DKK | 33.4% |
| 2022 Q1 | 506 Thousand DKK | 0.6% |
| 2021 Q4 | 503 Thousand DKK | 151.5% |
| 2021 Q3 | 200 Thousand DKK | -62.62% |
| 2021 Q2 | 535 Thousand DKK | 157.21% |
| 2021 FY | 1.44 Million DKK | 17.37% |
| 2021 Q1 | 208 Thousand DKK | 79.31% |
| 2020 Q1 | 177 Thousand DKK | 96.67% |
| 2020 Q2 | 435 Thousand DKK | 145.76% |
| 2020 Q3 | 504 Thousand DKK | 15.86% |
| 2020 FY | 1.23 Million DKK | 26.62% |
| 2020 Q4 | 116 Thousand DKK | -76.98% |
| 2019 Q4 | 90 Thousand DKK | -57.94% |
| 2019 FY | 973 Thousand DKK | -17.12% |
| 2019 Q3 | 214 Thousand DKK | -53.58% |
| 2019 Q2 | 461 Thousand DKK | 121.63% |
| 2019 Q1 | 208 Thousand DKK | -30.9% |
| 2018 Q3 | 271 Thousand DKK | -20.53% |
| 2018 FY | 1.17 Million DKK | -14.99% |
| 2018 Q4 | 301 Thousand DKK | 11.07% |
| 2018 Q1 | 261 Thousand DKK | -31.5% |
| 2018 Q2 | 341 Thousand DKK | 30.65% |
| 2017 FY | 1.38 Million DKK | 638.5% |
| 2017 Q1 | 329 Thousand DKK | -53.86% |
| 2017 Q3 | 332 Thousand DKK | -2.06% |
| 2017 Q4 | 381 Thousand DKK | 14.76% |
| 2017 Q2 | 339 Thousand DKK | 3.04% |
| 2016 Q4 | 713 Thousand DKK | 534.76% |
| 2016 Q2 | 3000.00 DKK | 0.0% |
| 2016 Q3 | -164 Thousand DKK | -5566.67% |
| 2016 FY | 187 Thousand DKK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| NextCell Pharma AB | -576.01 Thousand SEK | 100.628% |
| Biovica International AB (publ) | 133.72 Million SEK | 99.997% |
| Abliva AB (publ) | 27.86 Million SEK | 99.987% |
| Active Biotech AB (publ) | 44.8 Million SEK | 99.992% |
| Aptahem AB (publ) | 10.01 Million SEK | 99.964% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 99.999% |
| BioInvent International AB (publ) | 441.4 Million SEK | 99.999% |
| BioArctic AB (publ) | 89.62 Million SEK | 99.996% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 99.996% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 100.0% |
| Cantargia AB (publ) | 290.01 Million SEK | 99.999% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 99.983% |
| CombiGene AB (publ) | 44.14 Million SEK | 99.992% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 99.998% |
| Fluicell AB (publ) | 28.61 Million SEK | 99.987% |
| Genovis AB (publ.) | 88.19 Million SEK | 99.996% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 100.0% |
| Mendus AB (publ) | 129.13 Million SEK | 99.997% |
| Karolinska Development AB (publ) | 5.51 Million SEK | 99.934% |
| LIDDS AB (publ) | 27.75 Million SEK | 99.987% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 99.98% |
| Saniona AB (publ) | 1.07 Million SEK | 99.664% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 99.982% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 99.992% |
| Xintela AB (publ) | 57.31 Million SEK | 99.994% |
| Amniotics AB (publ) | 29.07 Million SEK | 99.988% |
| Corline Biomedical AB | 30.16 Million SEK | 99.988% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 99.987% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 99.997% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 99.994% |
| Intervacc AB (publ) | 79.78 Million SEK | 99.995% |
| Kancera AB (publ) | 63.07 Million SEK | 99.994% |
| Lipum AB (publ) | 37.3 Million SEK | 99.99% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | 99.95% |
| Nanologica AB (publ) | 69.88 Million SEK | 99.995% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 99.999% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 99.999% |
| AcouSort AB (publ) | 25.87 Million SEK | 99.986% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 99.997% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 99.997% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 99.997% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 99.978% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 99.998% |
| Simris Alg AB (publ) | 38.64 Million SEK | 99.991% |
| Ziccum AB (publ) | 27.87 Million SEK | 99.987% |
| SynAct Pharma AB | 224.49 Million SEK | 99.998% |
| OncoZenge AB (publ) | 15.9 Million SEK | 99.977% |
| Camurus AB (publ) | 1.05 Billion SEK | 100.0% |
| 2cureX AB (publ) | 36.51 Million SEK | 99.99% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 99.975% |
| Isofol Medical AB (publ) | 7.26 Million SEK | 99.95% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 99.985% |
| I-Tech AB | 40.14 Million SEK | 99.991% |
| Cyxone AB (publ) | 28.21 Million SEK | 99.987% |
| Biosergen AB | 26.8 Million SEK | 99.987% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 99.992% |
| Alzinova AB (publ) | 36.39 Million SEK | 99.99% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 99.999% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 99.997% |
| Pila Pharma AB (publ) | 7.85 Million SEK | 99.954% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 99.997% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 99.975% |